1-2 of 2
Paul Thornton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism

Available to Purchase
Subject Area:
Endocrinology , Women's and Children's Health
Paul Thornton, Lisa Truong, Courtney Reynolds, Tyler Hamby, Jonathan Nedrelow
Journal: Hormone Research in Paediatrics
Horm Res Paediatr (2019) 91 (1): 25–32.
https://doi.org/10.1159/000497458
Published Online: 19 March 2019
View articletitled, Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism
Open the PDF for Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism in another window
Journal Articles

A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing

Open Access
Subject Area:
Endocrinology , Women's and Children's Health
Debra R. Counts, Lawrence A. Silverman, Natasa Rajicic, Mitchell E. Geffner, Ron S. Newfield, Paul Thornton, Mauri Carakushansky, Oscar Escobar, Robert Rapaport, Lynne Levitsky, Deborah Rotenstein, Judith Hey-Hadavi, Michael P. Wajnrajch
Journal: Hormone Research in Paediatrics
Horm Res Paediatr (2015) 84 (2): 79–87.
https://doi.org/10.1159/000381642
Published Online: 01 May 2015
View articletitled, A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing
Open the PDF for A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing in another window